Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus

What Was Tested

This randomized controlled trial paper looks at Insulin Detemir and NPH Insulin (isophane).

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

The study was a randomized, double-blind, crossover 24-h-iso-glycemic clamp trial in 12 C-peptide-negative type 1 diabetic patients.

A detailed assessment of endogenous glucose production (EGP) and glucose uptake was performed, by use of stable isotopic labeled glucose tracer (D-[6,6- (2)H (2)] glucose).

How the Study Was Run

In design terms this was a randomized, double-blind and crossover study.

Random assignment meant chance, not the researchers, decided who got Insulin Detemir and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Insulin Detemir.

Each person switched between Insulin Detemir and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Area Under Curve, Blood Glucose, Diabetes Mellitus, Type 1, Glucose, Insulin, Insulin Detemir and Insulin, Isophane.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Detemir and NPH Insulin (isophane).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2007 (Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association), a journal based in Germany.

More context: the Insulin Detemir compound page and the NPH Insulin (isophane) compound page, all human trials.